-
Merck grows again in Va. with $3B small-molecule drug plant, part of planned $70B US outlay
20 Oct 2025 14:08 GMT
… molecule production and testing, Merck said. The facility, dubbed … front and center.
“Merck’s transformational $3 billion … manufacturing and life sciences.”
Merck has already revealed other … its medtech business. Meanwhile, Sanofi and Novartis have committed …
-
FDA Hands Out First Commissioner’s Priority Vouchers to Regeneron, Sanofi, Disc, Others
17 Oct 2025 14:19 GMT
… are:
- Merck KGaA’s Pergoveris for infertility
- Sanofi’s Tzield …
-
<![CDATA[From Slowing Decline to Restoring Function: Taladegib’s Promise in IPF, With Toby Maher, MD, PhD]]>
22 Oct 2025 16:14 GMT
… , Celgene, FibroGen, Genentech, GSK, Merck, PureTech Health, Sanofi, Trevi Therapeutics, and United …
-
Benchling Partners with Anthropic to Build a Bridge Between Science and AI
20 Oct 2025 16:40 GMT
… to global biopharmas like Merck, Moderna, and Sanofi. Benchling's products …
-
The Lancet: Study confirms cardiovascular benefits of semaglutide beyond weight loss
23 Oct 2025 00:38 GMT
… , Boehringer Ingelheim, Merck, Novartis,
Novo Nordisk, Pfizer, Sanofi, and Takeda; and … Ingelheim, Corcept, Esperion Therapeutics, Merck,
New Amsterdam, and Novo Nordisk … , Novo Nordisk, Pfizer, Procaps,
Sanofi-Aventis, Servier, and Tecnofarma. SB declares …
-
Obviousness-Type Double Patenting
23 Oct 2025 00:53 GMT
… 35 U.S.C. § 156. Merck & Co. v. Hi-Tech … be eligible for reissue; see Sanofi-Aventis U.S., LLC v. Dr …
-
Inside the FDA’s New Voucher Program: First 9 Picks Target Diabetes to Vaping
23 Oct 2025 01:36 GMT
… Alfa (Pergoveris)
Company: EMD Serono (Merck KGaA)
Indication: Infertility
Background Info … US.2
Teplizumab (Tzield)
Company: Sanofi
Indication: Type 1 Diabetes
A …
-
<![CDATA[What to Know About the Latest Pediatric Respiratory Infections]]>
22 Oct 2025 18:10 GMT
… as nirsevimab (Beyfortus; AstraZeneca, Sanofi) and clesrovimab (Enflonsia; Merck & Co) and …
-
Dupilumab Lessens COPD Exacerbation Impact, with Nicola Hanania, MD, MS
22 Oct 2025 02:21 GMT
… disclosures include Sanofi, Genzyme, Regeneron, GSK, AstraZeneca, Regeneron, Genentech, and Merck.
References …
-
Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight
21 Oct 2025 22:44 GMT
… ), itepekimab (Regeneron Pharmaceuticals/Sanofi), depemokimab (GSK), tozorakimab (AstraZeneca … ), itepekimab (Regeneron Pharmaceuticals/Sanofi), depemokimab (GSK), tozorakimab (AstraZeneca … Market
In July 2025, Merck entered into a definitive …
About
© 1995-2025